Navigation Links
Results of the STEMI-RADIAL trial presented at TCT 2012

MIAMI, FL OCTOBER 26, 2012 A study found several benefits in using the radial artery in the arm as the entry point for angioplasty or percutaneous coronary intervention (PCI) compared to the femoral artery in the leg. Results of the STEMI-RADIAL trial were presented today at the 24th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. Sponsored by the Cardiovascular Research Foundation (CRF), TCT is the world's premier educational meeting specializing in interventional cardiovascular medicine.

Recent data have demonstrated better clinical outcomes in patients undergoing primary PCI by the radial approach compared to the femoral approach. However, the experience of operators with the radial approach in previous trials has been variable. In the STEMI-RADIAL trial, investigators examined the net clinical benefit of using the radial versus femoral approach in patients presenting within 12 hours of symptom onset of acute ST-elevation myocardial infarction (STEMI). All investigators were high-volume (>200 PCI/year) operators with significant experience in the radial approach (>80% cases/year).

STEMI-RADIAL was a randomized, national, multicenter, parallel group trial conducted in 707 patients at four high-volume centers. Patients eligible for both access sites without cardiogenic shock were randomized to the radial or femoral access approach. The primary endpoint was the cumulative incidence of major bleeding and vascular access site complications (requiring intervention) at 30 days. Secondary endpoints included major adverse cardiovascular events (MACE: death, reinfarction and stroke), technical success, access site failure, procedural and fluoroscopy times, contrast volume, intensive care stay and target lesion revascularization.

The primary endpoint of major bleeding or access site complications occurred in 7.2 percent of the femoral access patients and 1.4 percent of the radial access patients (p=0.0001). The rate of MACE at 30 days was 4.2 percent in the femoral access group, and 3.5 percent in the radial access group (p=0.7).

"In patients with STEMI undergoing PCI within 12 hours, the radial approach was associated with a significantly lower incidence of major bleeding and access site complications, resulting in a significantly better net clinical benefit," said lead investigator Ivo Bernat, MD, PhD. Dr Bernat is an Assistant Professor of Medicine at University Hospital Pilsen in the Czech Republic.

"Moreover, the radial approach reduced significantly ICU stays and contrast volume compared to the femoral approach. Results of this trial support the use of the radial approach in primary PCI in high volume centers as a first choice," Dr. Bernat said.

The results of the STEMI-RADIAL trial will be presented on Friday October 26, 2012 at 11:55 AM in the Main Arena (Hall D) of the Miami Beach Convention Center.


Contact: Judy Romero
Cardiovascular Research Foundation

Related medicine news :

1. Results of the XIMA trial presented at TCT 2012
2. Results of the AIDA STEMI MRI sub-study presented at TCT 2012
3. Results of the PC trial presented at TCT 2012
4. Results of the POSEIDON trial presented at TCT 2012
5. 1-year results of ADAPT-DES presented at TCT 2012
6. Comparison of Obesity Surgeries Turns Up Surprising Results
7. Results from study of Mead Johnsons Enfamil® Human Milk Fortifier Acidified Liquid published in Pediatrics
8. Missed Diagnoses in ICU Often Have Deadly Results: Review
9. Anti-clotting drugs yield similar results
10. Late-Night Cramming May Hurt School Test Results
11. New survey: Women want to SEE breast reconstruction results before cancer surgery
Post Your Comments:
(Date:10/13/2017)... ... October 13, 2017 , ... Dickinson ... offers insurance and financial preparation services, is providing an update on a charitable ... , Rock City Rescue is a locally recognized nonprofit that provides shelter and ...
(Date:10/13/2017)... Nevada (PRWEB) , ... October 13, 2017 , ... ... Hemp CBD Oil utilizing Purzorb™ technology. Applying the Purzorb™process to full spectrum CBD oil ... required and providing a CBD form that can be easily incorporated into liquid products, ...
(Date:10/13/2017)... ... , ... The Visiting Nurse Association (VNA) of Somerset Hills is proud to ... unique items from across the nation, this holiday-themed event will raise funds and awareness ... VNA. The boutique will be open Saturday, November 4 (10:00 a.m. – 5:00 ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... Agile Software Development, has been awarded a contract by the Center for Medicare ... (BPA) aims to accelerate the enterprise use of Agile methodologies in a consistent ...
(Date:10/12/2017)... Orleans, LA (PRWEB) , ... October 12, 2017 , ... ... centers in the U.S., announced today its plans to open a flagship location in ... will occupy the former Rooms To Go store next to Office Depot in the ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... Mich. , Oct. 2, 2017 Diplomat ... 8th Day Software and Consulting, LLC , and ... 8th Day Software, based in Tennessee ... LLC. 8th Day expands EnvoyHealth,s service offerings for health ... development. "In an ...
(Date:9/28/2017)... CHICAGO , Sept. 28, 2017 Hill-Rom ... quarter 2017 earnings conference call and webcast on Friday, ... 8:00 a.m. (EDT) and ending at approximately 8:30 a.m. ... to discussing the company,s 2017 financial performance and guidance ... growth opportunities, initiatives to enhance operational performance, and long-range ...
(Date:9/25/2017)... PROVIDENCE, R.I. , Sept. 25, 2017 /PRNewswire/ ... immunogenicity assessment, vaccine design, and immune-engineering today announced ... focused on the development of personalized therapeutic cancer ... and has provided exclusive access to enabling technologies ... MSc Eng., MBA will lead EpiVax Oncology as ...
Breaking Medicine Technology: